Obsidian Therapeutics Reports Zero Revenue and Assets in Initial Financial Performance

Obsidian Therapeutics, Inc., formerly known as Gazelle Parent, Inc., has reported its financial performance for the period from its inception on April 10, 2026, to June 30, 2026. The company, which is focused on developing engineered tumor infiltrating lymphocyte cell therapies for solid tumors, has not yet generated any revenue or incurred any expenses during this initial reporting period. As of June 30, 2026, the company reported total assets and liabilities of zero, with stockholder equity also recorded at zero, reflecting its early-stage status.

The company underwent significant structural changes during this period, completing a merger transaction on August 3, 2026, as outlined in the Agreement and Plan of Merger dated April 14, 2026. This merger involved Obsidian Merger Sub merging with Gazelle Parent, Inc., and subsequently, Galera Merger Sub merging with Galera Therapeutics, Inc. Following these transactions, the company was renamed Obsidian Therapeutics, Inc. Additionally, a securities purchase agreement was executed, resulting in an aggregate purchase price of $350 million from qualified institutional buyers for Series C Non-Voting Convertible Preferred Stock.

In terms of operational developments, the company has established two wholly-owned subsidiaries, Onyx MergerSub, Inc. and Gazelle Merger Subsidiary, Inc., to facilitate its business operations. The company has also initiated a Contingent Value Rights Agreement, which entitles stockholders of Legacy Galera to potential future net proceeds from the development and commercialization of certain products. However, the company has not disclosed specific customer counts, user statistics, or market share figures, as it is still in the early stages of its business model.

Looking ahead, Obsidian Therapeutics is positioned to leverage its novel protein-regulation technology to advance its clinical-stage biopharmaceutical initiatives. The company’s management has indicated that it will focus on the development and commercialization of its engineered therapies, although specific financial forecasts or performance metrics have not been provided at this time. The completion of the merger and the associated financing are expected to provide the necessary capital to support its strategic objectives in the biopharmaceutical sector.